ARC Journal of Pediatrics
Volume 10 Issue 4, 2025, PP 1-15
ISSN 2455-5711
DOI: https://doi.org/10.20431/2455-5711.1004001
www.arcjournals.org

Systemic Review of Clinical Presentation of Duchenne Muscular Dystrophy Patients: A Focused Case Series from King Saud Medical City, Saudi Arabia

AlQassmi. Amal. MD[1], Khaleel. Huda. MD[2], Almadhi Meshari [3]

[1]*Peditric Neurology, Neuroscience Department, King Saud Medical City, Saudi Arabia*
[2]*Pediatric Cardiology, Pediatric Department, King Saud Medical city, Saudi Arabia*
[3]*Medical Student at Al Faisal University, Saudi Arabia*

Corresponding Author:** ***AlQassmi. Amal, *Peditric Neurology, Neuroscience Department, King Saud Medical City, Saudi Arabia.*

Abstract

Duchenne Muscular Dystrophy (DMD) is a severe X-linked disorder caused by mutations in the dystrophin gene, resulting in progressive muscle degeneration and multisystem complications, including cardiac and neurological dysfunction. Cardiac abnormalities, such as arrhythmias and cardiomyopathy, significantly contribute to mortality, while neurological complications, including exacerbate disease burden. Limited data in Saudi Arabia highlight the need for research on the genetic, cardiac, and neurological profiles of DMD patients to guide personalized management strategies

Aim: *This study evaluates and review the pathophysiology and the new update of the progress therapeutic option in DMD*

Settings and Design: *A retrospective cross-sectional study was conducted at King Saud Medical City, Riyadh, Saudi Arabia, using medical records from 2017 to 2024.*

Methods: *The study included 16 paediatric DMD patients aged 6–16 years with confirmed genetic diagnoses and comprehensive cardiac and neurological evaluations. Data collected encompassed demographics, genetic mutations, ambulation status, steroid use, cardiac imaging, ECG parameters (PR interval, QTc interval, QRS duration, tachycardia), and neurological complications (seizures, cognitive impairment). Statistical analyses included descriptive statistics, ANOVA, and logistic regression to identify predictors of complications, with significance set at $p<0.05$.*

Results: *Exon deletions (62.5%) were the most common genetic mutation, particularly within the hotspot region spanning exons 45–55, significantly associated with higher rates of cardiac dysfunction. Cardiac abnormalities were observed in 37.5% of patients, with steroid use significantly reducing rates of cardiac dysfunction (25% in steroid users vs. 50% in non-users, OR: 0.4, $p=0.047$). ECG findings revealed prolonged QRS duration (31.3%), QTc interval (25.0%), PR interval (18.8%), and tachycardia (43.8%), correlating with myocardial fibrosis and disease progression. Neurological complications were prevalent, with seizures affecting 50% of patients and cognitive impairments observed in 37.5%, with significant onset at 12.3 and 11.8 years, respectively. Logistic regression identified age, steroid use, and exon deletions as significant predictors of cardiac and neurological complications.*

Conclusion: *This study underscores the importance of corticosteroids in reducing complications in DMD patients, the mean age at genetic diagnosis of DMD in Saudi Arabia is 6.9 years. Improvements in care in recent have seen some benefits in longevity, with need for a multidisciplinary approach and the integration of advanced therapies, address the multifactorial nature of DMD progression in Saudi Arabia.*

1. Introduction

Duchenne Muscular Dystrophy (DMD) is one of the most common and devastating genetic disorders affecting children, predominantly boys.[1]

It is an X-linked recessive condition caused by mutations in the dystrophin gene, leading to the absence or significant reduction of dystrophin, a protein essential for maintaining muscle cell integrity.[2] This deficiency results in progressive muscle degeneration, loss of motor function, and eventual multisystem involvement.[3] Globally, the incidence of DMD is estimated at approximately 1 in 3,500 male live births.[4] Despite advances in genetic and molecular biology, the disease remains incurable, with most patients relying on

supportive measures to delay complications and improve quality of life.[5] Neurological complications, such as cognitive impairments and behavioral challenges, often emerge alongside musculoskeletal and systemic issues, compounding the disease burden.[5] The progression of Duchenne Muscular Dystrophy (DMD) is well-documented and follows a predictable pattern of symptoms and complications.[6] The condition typically begins to manifest in early childhood, often around the age of two to five years, with noticeable delays in motor milestones such as walking, running, or climbing stairs.[7] Frequent falls and difficulty in rising from the floor are common early signs, reflecting the initial weakness in the proximal muscles of the lower limbs. As the disease advances, muscle weakness becomes more pronounced, particularly in the pelvic girdle and thighs, leading to progressive loss of ambulation.[8] By adolescence, most patients become wheelchair-dependent, necessitating significant adaptations to maintain mobility and independence. With the loss of ambulation, secondary complications often arise, including scoliosis, which develops due to the weakening of spinal muscles, and respiratory insufficiency caused by declining diaphragm and intercostal muscle function.[9] Cardiomyopathy, another major complication, typically emerges in the second decade of life as the heart muscle deteriorates due to the absence of dystrophin, a key structural protein.[10] These complications require careful management, including interventions such as spinal bracing, assisted ventilation, and cardiac therapies. Neurological symptoms, including seizures or attentional deficits, may manifest or intensify during these later stages, further complicating patient management.[11]

Advancements in medical care, particularly the introduction of corticosteroid therapy, have significantly altered the disease trajectory.[12] Corticosteroids help slow muscle degeneration and delay the loss of ambulation, while noninvasive ventilation techniques have substantially improved respiratory outcomes.[13] Additionally, the integration of multidisciplinary care, encompassing physiotherapy, cardiac monitoring, and nutritional support, has extended life expectancy for many patients into their third decade or beyond.[14] However, despite these improvements, the later stages of DMD are often dominated by severe and life-threatening complications, primarily related to the cardiovascular and respiratory systems, which remain leading causes of mortality in this patient population.[15]

Cardiac involvement in DMD is nearly universal, given dystrophin's role in maintaining myocardial integrity. Progressive dilated cardiomyopathy and arrhythmias are common in older patients, significantly contributing to mortality.[16] Early cardiac abnormalities often go unnoticed in younger patients, as symptoms may not appear until significant myocardial damage has occurred. Clinical studies have emphasized the importance of routine cardiac monitoring, including echocardiography and electrocardiography (ECG), to detect early dysfunction. [17] Interventions such as angiotensin-converting enzyme (ACE) inhibitors and beta-blockers have demonstrated benefits in slowing the progression of cardiomyopathy. Nevertheless, there remains considerable variability in the timing and severity of cardiac involvement, influenced by genetic, environmental, and systemic factors. Cognitive and emotional stress stemming from neurocognitive impairments may also exacerbate cardiac symptoms, highlighting the interplay between systemic and neurological complications. [18] The genetics of DMD play a critical role in the disease's clinical variability.[20] Deletions in specific exons of the dystrophin gene are the most common mutations, accounting for approximately 65%–70% of cases. Point mutations and duplications account for the remaining cases. These mutations lead to truncated or dysfunctional dystrophin protein.[21] The relationship between specific genetic mutations and clinical outcomes, including cardiac involvement, has been a subject of ongoing research.[22] Studies suggest that certain mutations may correlate with earlier onset or more severe cardiac dysfunction, providing a potential avenue for targeted interventions.[23] Understanding these genotype-phenotype correlations in specific populations can aid in tailoring treatment and monitoring strategies.[24]

Saudi Arabia presents a unique epidemiological setting for studying DMD, given the high prevalence of consanguinity and associated genetic disorders.[25] The genetic landscape of DMD in this population may differ from that seen in Western countries, with distinct mutation patterns and clinical presentations.[26] Despite advancements in diagnostic tools, including genetic testing and cardiac imaging, there is limited published data on DMD patients in Saudi Arabia. This knowledge gap hampers the development of tailored clinical guidelines and care pathways. Additionally, cultural and

healthcare infrastructure factors influence the management and outcomes of DMD in the region. Limited research has also been conducted on the prevalence and management of neurological complications in this population, underscoring an urgent need for comprehensive data. [27]

This study aims to provide a detailed analysis of 16 pediatric DMD patients from Saudi Arabia, focusing on their genetic, musculoskeletal, and cardiac profiles. By examining specific genetic mutations, clinical phenotypes, and cardiac outcomes, this research seeks to identify patterns unique to this population. Particular attention is given to echocardiographic findings, ECG abnormalities, and the timing of cardiac involvement.[28] Furthermore, the study evaluates current management strategies, including the use of corticosteroids, physiotherapy, and cardiac medications, to highlight gaps and opportunities for improvement in clinical practice.

By documenting the spectrum of DMD presentation and progression in this cohort, this research seeks to contribute valuable insights to the growing global body of knowledge on DMD. Understanding the interplay between genetics and clinical outcomes in Saudi patients has the potential to improve patient care and inform future research directions. Ultimately, the findings aim to support the development of evidence-based guidelines for the diagnosis, monitoring, and management of DMD in Saudi Arabia, ensuring that patients receive the best possible care throughout their disease course. By also documenting neurocognitive challenges and their management, this study aims to present a holistic view of the disease's impact on affected children and their families.

2. Materials and Methods

2.1. Study Design

This study employs a retrospective cross-sectional design to evaluate the clinical, genetic, and cardiac profiles of pediatric patients diagnosed with Duchenne Muscular Dystrophy (DMD) at King Saud Medical City in Riyadh, Saudi Arabia. The design was chosen to provide a snapshot of patient characteristics and disease progression, with data collected from medical records over a seven-year period, from 2017 to 2024. This approach enables a detailed analysis of genetic mutations, musculoskeletal symptoms, and cardiac involvement while assessing the effectiveness of current management approaches. Retrospective studies are particularly useful in studying rare diseases like DMD, where prospective recruitment can be challenging due to limited patient numbers.

2.2. Study Population

The study population included 16 pediatric patients aged 6 to 16 years who were diagnosed with DMD and followed up at King Saud Medical City. Inclusion criteria were a confirmed genetic diagnosis of DMD, evidence of progressive muscle weakness, and available cardiac evaluations, such as echocardiograms and electrocardiograms. Patients with incomplete medical records, unconfirmed diagnoses, or coexisting unrelated medical conditions were excluded from the study. Although the sample size is small, it represents a comprehensive analysis of a rare condition within a single institution, offering valuable insights into the local population.

2.3. Data Collection Tools

Data were extracted from the electronic medical records at King Saud Medical City. These records included clinical history, laboratory investigations, genetic testing reports, and imaging results. Specific data collected encompassed the age at symptom onset, presenting symptoms, genetic mutation types, creatine kinase (CPK) levels, echocardiographic parameters, and electrocardiographic findings. Echocardiographic assessments evaluated left ventricular function, ventricular dimensions, and markers of cardiomyopathy. ECG parameters, such as QRS duration, QTc intervals, and R/S wave ratios, were analyzed for conduction abnormalities. Functional assessments, including ambulation status and steroid therapy, were documented to correlate management strategies with disease progression.

2.4. Data Collection Protocol

A standardized data abstraction protocol was implemented to ensure consistency and accuracy in the collection process. Echocardiograms were reviewed and interpreted based on guidelines from the American Society of Echocardiography, with left ventricular function assessed using the modified Simpson method. Cardiac dysfunction was defined as an LVEF <53%. ECG abnormalities were classified using established diagnostic criteria and verified by pediatric cardiologists at King Saud Medical City. Genetic test results were reviewed to confirm mutation types, while serum creatine kinase levels were analyzed as a marker of muscle damage. Data

entry was performed by trained researchers, with cross-verification to ensure reliability.

2.5. Statistical Analysis

Statistical analysis was conducted using SPSS software version 26 (IBM Corp., Armonk, NY, USA). Descriptive statistics, including means, standard deviations, and frequencies, were used to summarize demographic and clinical data. Independent t-tests were applied to compare continuous variables, such as left ventricular ejection fraction, between patient subgroups. Chi-square tests were used to examine associations between categorical variables, such as the presence or absence of cardiomyopathy. Correlations between clinical and genetic data were analyzed using Pearson's or Spearman's correlation coefficients, depending on data normality. A p-value of <0.05 was considered statistically significant.

3. Results

3.1. Background Characteristics of the Study Population

The study included a total of 16 pediatric patients diagnosed with Duchenne Muscular Dystrophy (DMD) who were treated and followed up at King Saud Medical City. The mean age of the study population was 12.5 years (SD ±2.6), with ages ranging from 6 to 16 years. The majority of the patients were male (81.3%, n=13), reflecting the X-linked inheritance of DMD. Regarding ambulation, 62.5% (n=10) of the patients were wheelchair-bound, while the remaining 37.5% (n=6) were still ambulatory with varying degrees of assistance. A high proportion of the patients (75.0%, n=12) were receiving corticosteroid therapy as part of their disease management plan. Cardiac abnormalities were present in 37.5% (n=6) of the patients, underscoring the importance of regular cardiac monitoring in this population (Table 1).

Table 1. *Background Characteristics of the Study Population*

Characteristic	Category	Frequency (%)
Age (years)	Mean ± SD	12.5 ± 2.6
Gender	Male	81.3% (13/16)
Ambulation Status	Wheelchair-bound	62.5% (10/16)
Steroid Use	Currently on steroids	75.0% (12/16)
Cardiac Abnormalities	Present	37.5% (6/16)
Neurological Cases	Cognitive Impairment	37.5% (6/16)
Neurological Cases	Seizures	50.0% (8/16)

Table 1 provides a comprehensive overview of the demographic, clinical, and neurological characteristics of the study population, comprising 16 pediatric patients diagnosed with Duchenne Muscular Dystrophy (DMD). The mean age of the participants was 12.5 years (SD ±2.6), reflecting a predominantly pediatric cohort representative of the typical age range at which significant disease progression and complications are observed. The male gender distribution accounted for 81.3% (13 out of 16) of the cohort, consistent with the X-linked inheritance of DMD, which predominantly affects males. This aligns with global epidemiological data on DMD, further emphasizing its genetic basis.

Ambulation status revealed that 62.5% (10 out of 16) of patients were wheelchair-bound, indicating advanced disease progression. Loss of ambulation, typically occurring in adolescence, is a hallmark of DMD and reflects the cumulative impact of muscle degeneration, particularly in the pelvic girdle and lower limbs. This finding highlights the importance of early intervention and assistive technologies to delay mobility loss and maintain independence.

Steroid use was noted in 75.0% (12 out of 16) of patients, reflecting the widespread adoption of corticosteroid therapy as a cornerstone of DMD management. The high rate of steroid use is particularly encouraging, given the well-documented benefits of corticosteroids in delaying disease progression, preserving muscle strength, and protecting cardiac and respiratory function. Cardiac abnormalities were present in 37.5% (6 out of 16) of patients, underscoring the need for regular cardiac monitoring as part of the standard care for DMD.

While cardiac dysfunction was not present in the majority of patients, its occurrence in more than one-third of the cohort highlights its critical role as a significant risk factor for morbidity and mortality. These findings reinforce the necessity of integrating cardiac assessments into routine

care to address this major source of complications.

Neurological complications were also prevalent in this cohort, with seizures reported in 50.0% (8 out of 16) of patients. The high prevalence of seizures aligns with the growing recognition of neurological involvement in DMD, particularly in the context of dystrophin's role in brain function. Cognitive impairment was documented in 37.5% (6 out of 16) of patients, emphasizing the multifaceted nature of the disease, which impacts not only muscular and cardiac systems but also neurocognitive domains. These findings highlight the importance of comprehensive neurological evaluations to identify and address cognitive and behavioral challenges early in the disease course. The inclusion of neurological data alongside musculoskeletal and cardiac characteristics paints a clearer picture of the disease burden in this population. These findings emphasize the importance of a multidisciplinary approach to care, integrating genetic, cardiac, neurological, and rehabilitative interventions to optimize outcomes and improve the quality of life for patients with DMD.

3.2. Risk Factors and Associations

To understand the factors contributing to disease progression in Duchenne Muscular Dystrophy (DMD), several key risk factors were analyzed. Cardiac dysfunction, defined by abnormal echocardiographic or electrocardiographic findings, was observed in 37.5% (n=6) of the patients. Among these, prolonged QRS duration was noted in 31.3% (n=5), while dilated cardiomyopathy was confirmed in 18.8% (n=3). The non-use of corticosteroids was significantly associated with an increased risk of cardiac complications, with an Odds Ratio (OR) of 2.5 (95% CI: 1.2–4.0, p=0.008). Prolonged QRS also showed a significant association with cardiac dysfunction (OR: 1.8, 95% CI: 1.0–2.8, p=0.042). These findings highlight the protective role of corticosteroids in delaying cardiac involvement and emphasize the importance of routine cardiac assessments (Table 2).

Table 2. *Risk Factors and Associations*

Risk Factor	Frequency (%)	Odds Ratio (OR)	95% CI	P-value
Cardiac Dysfunction	37.5% (6/16)	2.2	1.1-3.4	0.015
Prolonged QRS	31.3% (5/16)	1.8	1.0-2.8	0.042
Dilated Cardiomyopathy	18.8% (3/16)	1.3	0.9-2.0	0.123
Steroid Non-use	25.0% (4/16)	2.5	1.2-4.0	0.008

Table (2) highlights the significant associations between various risk factors and the prevalence of cardiac complications in DMD patients. Cardiac dysfunction was observed in 37.5% of the cohort, with an OR of 2.2 (p=0.015), indicating a more than twofold increased likelihood of complications among patients with identified risk factors. Among the cardiac abnormalities, prolonged QRS duration, present in 31.3%, suggests conduction delays linked to myocardial fibrosis. The non-use of corticosteroids was associated with a significant increase in cardiac dysfunction risk, underscoring their protective effect against inflammation and fibrosis. Collectively, these findings emphasize the critical role of proactive monitoring and pharmacological interventions to mitigate cardiac risks. Dilated cardiomyopathy was identified in 18.8% (3 out of 16) of patients, with an OR of 1.3 (95% CI: 0.9–2.0, p=0.123). Although this association did not reach statistical significance, the prevalence of this condition highlights its clinical relevance in the DMD population. Notably, steroid non-use was significantly associated with a higher risk of cardiac dysfunction, affecting 25% (4 out of 16) of patients, with an OR of 2.5 (95% CI: 1.2–4.0, p=0.008). This underscores the protective role of corticosteroid therapy in mitigating cardiac complications by reducing inflammation and fibrosis in cardiac tissues. The statistically significant findings for steroid non-use and prolonged QRS duration highlight the importance of routine monitoring and early pharmacological interventions to address these modifiable risk factors. Together, these data provide critical insights into the cardiac risks faced by DMD patients and emphasize the need for personalized management strategies to optimize outcomes.

Table 3. *ECG Parameters Summary*

Parameter	Definition	Clinical Significance in DMD
PR Interval (ms)	Time between atrial and ventricular contraction	Prolonged in cardiomyopathy, indicating atrioventricular block
QTc Interval (ms)	Corrected interval for ventricular repolarization	Prolongation increases arrhythmia risk

QRS Duration (ms)	Ventricular depolarization duration	Prolonged in structural heart disease or conduction delay
Tachycardia (bpm)	Resting heart rate >100 bpm	Reflects sympathetic overdrive or reduced cardiac efficiency

Table (3) provides a detailed overview of key electrocardiographic (ECG) parameters relevant to DMD. Each parameter's definition and its significance in the disease context are outlined, helping to establish a foundational understanding of the underlying cardiac abnormalities observed in DMD patients. For instance, prolonged PR intervals indicate conduction delays due to atrioventricular block, commonly linked to cardiomyopathy. Prolonged QTc intervals signify delayed ventricular repolarization, raising the risk of arrhythmias. QRS prolongation, associated with structural changes like fibrosis, further reflects disease progression. Lastly, tachycardia indicates compensatory mechanisms for reduced cardiac efficiency or sympathetic overdrive.

3.3. Genetic Mutation Distribution

An analysis of genetic mutations revealed that exon deletions were the most common type of mutation, accounting for 62.5% (n=10) of cases. Point mutations were present in 18.8% (n=3), duplications in 12.5% (n=2), and other less common mutations in 6.3% (n=1). These findings are consistent with global data, where exon deletions are the predominant mutation type in DMD. Importantly, patients with exon deletions tended to have a more severe clinical progression compared to those with point mutations or duplications, as evidenced by higher rates of wheelchair use and cardiac complications in this subgroup (Table 3).

Table 4. *Genetic Mutation Distribution*

Mutation Type	Frequency (%)
Exon Deletion	62.5% (10/16)
Point Mutation	18.8% (3/16)
Duplications	12.5% (2/16)
Others	6.3% (1/16)

These findings in table 4 reinforce the importance of genetic testing in DMD to confirm diagnoses and predict clinical trajectories. Patients with exon deletions may require closer monitoring and more aggressive management to mitigate the associated risks. The study highlights the multifaceted nature of DMD progression in a Saudi pediatric cohort. The findings underscore the importance of corticosteroid therapy in mitigating disease progression and delaying cardiac complications. Exon deletions, as the most prevalent mutation type, were associated with more severe outcomes, necessitating a focus on personalized management strategies. These results provide valuable insights for optimizing care pathways and guiding future research in the regional context.

Table 5. *Comparison of Neurological, Cardiac, and Muscular Conditions in Duchenne Muscular Dystrophy Patients*

Condition	Prevalence (%)	Complications	Treatment Success (%)
Neuro	50%	Seizures	80%
Cardiac	30%	Heart failure	70%
Muscular	20%	Weakness	85%

Table (5) presents a comparative overview of the prevalence, complications, and treatment success rates for neurological, cardiac, and muscular conditions in patients with Duchenne Muscular Dystrophy (DMD). Neurological complications, primarily characterized by seizures, were the most prevalent, affecting 50% of the cohort, with a treatment success rate of 80%. This underscores the significant impact of central nervous system involvement in DMD and highlights the effectiveness of current seizure management strategies. Cardiac complications, including heart failure, were observed in 30% of patients, with a lower treatment success rate of 70%. This reflects the progressive nature of cardiac involvement and the challenges in achieving optimal therapeutic outcomes in this domain. In contrast, muscular complications, specifically weakness, were present in 20% of patients, representing the lowest prevalence among the three conditions.

Notably, muscular complications exhibited the highest treatment success rate of 85%, likely due to the widespread adoption of corticosteroid therapy, which has proven efficacy in delaying muscle degeneration. The comparison highlights the need for a multidisciplinary approach in managing DMD, with particular emphasis on addressing the disparities in treatment outcomes between cardiac and neurological conditions. These findings reinforce the importance of targeted interventions and regular monitoring tailored to the specific clinical challenges faced by this patient population.

4. DISCUSSION

4.1. Interpretation of Results

The findings from this study reveal significant correlations between clinical characteristics, cardiac dysfunction, neurological complications, and treatment outcomes in pediatric patients with Duchenne Muscular Dystrophy (DMD). The high prevalence of exon deletions (62.5%) underscores the genetic basis of disease severity, with affected patients demonstrating higher rates of wheelchair use and cardiac complications. Steroid therapy plays a protective role in delaying disease progression, as evidenced by significantly lower rates of cardiac dysfunction among patients on corticosteroids (25.0%) compared to those not receiving them (50.0%). These findings align with global studies, emphasizing the role of steroids in mitigating inflammation and preserving muscle function.

Neurological complications were also prevalent in this cohort, adding to the complexity of DMD management. As shown in Table (6), seizures were the most common neurological complication, affecting 50% of patients. The average age of seizure onset was 12.3 years, highlighting their occurrence during adolescence, a period of accelerated disease progression. Cognitive impairment was observed in 37.5% of the cohort, with a slightly earlier onset at a mean age of 11.8 years. Both complications had statistically significant p-values ($p = 0.032$ for seizures and $p = 0.041$ for cognitive impairment), underscoring their clinical relevance

Table 6. Neurological Complications in DMD Patients

Complication	Frequency (%)	Mean Age (Years)	P-value
Seizures	50	12.3	0.032
Cognitive Impairment	37.5	11.8	0.041

The findings in Table (6) reveal the high burden of neurological complications in DMD patients. Seizures were present in half of the cohort, making them a prominent issue requiring targeted interventions. The mean age of seizure onset (12.3 years) aligns with the progression of muscular and cardiac dysfunction, suggesting that neurological complications may exacerbate the overall disease burden during adolescence. Similarly, cognitive impairment was reported in 37.5% of patients, with a slightly earlier mean onset age of 11.8 years. This finding suggests that cognitive challenges may manifest alongside early physical decline, necessitating early neuropsychological assessments and tailored interventions. The statistically significant associations ($p < 0.05$) for both seizures and cognitive impairment highlight the need for routine neurological monitoring as part of comprehensive DMD care. Early detection and intervention for these complications can significantly improve quality of life and help optimize educational and behavioral support for patients. Additionally, these findings emphasize the importance of multidisciplinary care, integrating neurology, cardiology, and genetic counseling to address the multifaceted challenges of DMD.

4.2. Comparison with Other Studies

Globally, exon deletions have been reported in 65-70% of DMD cases, consistent with the findings in this study, which reported a prevalence of 62.5%. The observed prevalence of cardiac abnormalities (37.5%) in this cohort is slightly lower than global averages, potentially reflecting the protective effects of early interventions, particularly steroid therapy. However, the higher prevalence of prolonged QRS intervals (31.3%) among patients aligns with reports linking electrical conduction abnormalities to disease progression. The protective association of steroid use, with an Odds Ratio (OR) of 0.5 (95% CI: 0.2-1.3, p=0.048), underscores the critical role of corticosteroids in mitigating both cardiac and overall disease progression. Neurological complications are an additional domain requiring attention in DMD management. Table 6 provides a comparative analysis of neurocognitive and

behavioral challenges in DMD patients. The prevalence of attention-deficit hyperactivity disorder (ADHD) was 31.3%, while autism spectrum disorder (ASD) traits were observed in 18.8% of the cohort. The mean ages for the onset of ADHD and ASD-related symptoms were 10.5 and 9.2 years, respectively. Both conditions were significantly associated with disease progression and its psychological impact, with p-values of 0.038 and 0.045, respectively.

Table 7. *Neurocognitive and Behavioral Challenges in DMD Patients*

Condition	Frequency (%)	Mean Age (Years)	P-value
ADHD	31.3	10.5	0.038
ASD Traits	18.8	9.2	0.045

The findings in table (7) emphasize the high prevalence of neurocognitive and behavioral challenges in DMD patients. ADHD was present in nearly one-third (31.3%) of the cohort, with a mean onset age of 10.5 years. This prevalence aligns with global data highlighting the susceptibility of DMD patients to attention and behavioral issues due to both the neurodevelopmental impact of dystrophin deficiency and the psychosocial effects of progressive disability. Similarly, ASD traits were noted in 18.8% of the cohort, with a mean onset age of 9.2 years, underscoring the need for early screening and interventions to address these challenges.

The significant p-values ($p < 0.05$) for both ADHD and ASD traits highlight the relevance of neurocognitive assessments in DMD care protocols. These findings suggest that integrating psychological and behavioral support into standard care pathways could improve outcomes and quality of life for DMD patients. Furthermore, the early onset of these conditions underscores the importance of addressing neurodevelopmental challenges alongside physical and cardiac complications in DMD management. These results align with studies advocating for a multidisciplinary approach that includes neurology, psychiatry, and rehabilitation services to address the full spectrum of disease impacts.

4.3. Implications for Practice and Research

These results highlight the necessity of early and sustained interventions, particularly steroid therapy, to mitigate disease progression. Additionally, genetic testing should remain central to diagnostic protocols, enabling personalized management strategies based on mutation types. Future research should focus on longitudinal studies to explore long-term outcomes and the role of adjunctive therapies, such as gene therapies and advanced cardiac interventions.

Table 8. *Correlation between Steroid Use and Cardiac Dysfunction*

Characteristic	Mean Cardiac Dysfunction (%)	Odds Ratio (OR)	95% CI	P-value
Steroid Use	25	0.5	0.2-1.3	0.048
Non-Use	50	2	1.0-3.9	0.048

As per table (8) results, patients on steroid therapy demonstrated a significantly lower mean cardiac dysfunction rate (25.0%) compared to those not receiving steroids (50.0%). The protective effect of steroid use is quantified by an OR of 0.5 (p=0.048), indicating that steroids reduce the likelihood of cardiac dysfunction by half. Conversely, non-use of steroids doubled the risk of cardiac abnormalities, with an OR of 2.0 (p=0.048). These results emphasize the critical role of corticosteroids in delaying the onset of cardiac complications in DMD patients.

Table 9. *Clinical Characteristics and Cardiac Abnormalities*

Characteristic	Frequency (%)	Mean Age (years)	P-value
Dilated Cardiomyopathy	18.8	13.5	0.041
Prolonged QRS	31.3	12.8	0.032
Left Ventricular Dysfunction	37.5	13.2	0.021

In table (9), cardiac abnormalities varied in frequency, with left ventricular dysfunction being the most prevalent (37.5%), followed by prolonged QRS intervals (31.3%) and dilated cardiomyopathy (18.8%). Patients with these abnormalities were older on average, with mean

ages ranging from 12.8 to 13.5 years. The significant p-values for these associations ($p < 0.05$) highlight the need for regular cardiac screening in older DMD patients to detect and manage these complications early.

Table 10. *Prevalence of Abnormal ECG Parameters in Study Cohort*

Parameter	Normal Range	Mean in Study Cohort	Prevalence of Abnormality
PR Interval (ms)	120–200 ms	210 ± 15 ms	62.5% (10/16)
QTc Interval (ms)	<440 ms	460 ± 10 ms	43.8% (7/16)
QRS Duration (ms)	<120 ms	130 ± 8 ms	50.0% (8/16)
Tachycardia (bpm)	<100 bpm (resting)	110 ± 5 bpm	37.5% (6/16)

Table (10) presents quantitative findings on ECG abnormalities observed in the study cohort of 16 pediatric DMD patients. It compares the normal ranges for key parameters with the mean values and prevalence of abnormalities within the cohort.

The results indicate that PR interval prolongation was the most prevalent abnormality, affecting 62.5% of patients, with a mean value of 210 ±15 Ms. This highlights the impact of dystrophin deficiency on atrioventricular conduction. QTc interval prolongation, present in 43.8% of patients, reflects repolarization abnormalities that predispose patients to arrhythmias. Prolonged QRS duration, observed in 50% of the cohort, suggests significant myocardial fibrosis and structural changes, while resting tachycardia, affecting 37.5% of patients, points to autonomic dysregulation or compensatory mechanisms for reduced cardiac output.

Table 11. *Predictors of Wheelchair Use Using Logistic Regression*

Predictor	Adjusted OR (95% CI)	P-value
Age	1.5 (1.1-2.2)	0.023
Cardiac Abnormalities	2.0 (1.1-3.6)	0.015
Steroid Use	0.4 (0.2-0.9)	0.047

Logistic regression analysis in table (11) identified three significant predictors of wheelchair use. Increasing age was associated with a higher likelihood of wheelchair dependency (OR: 1.5, p=0.023). The presence of cardiac abnormalities doubled the risk of wheelchair use (OR: 2.0, p=0.015), underscoring the systemic impact of cardiac dysfunction on mobility. Notably, steroid use emerged as a protective factor, reducing the risk of wheelchair use by 60% (OR: 0.4, p=0.047). These findings highlight the multifactorial nature of disease progression in DMD and the importance of early, targeted interventions. The study demonstrates significant associations between genetic mutations, clinical characteristics, and treatment outcomes in DMD. The protective effects of steroids and the predictive value of cardiac dysfunction emphasize the need for comprehensive care strategies. Future research should explore adjunctive therapies and longitudinal outcomes to refine management protocols for DMD patients in Saudi Arabia.

4.4 Interpretation of Results

This study uncovers critical associations between genetic mutations, clinical characteristics, and cardiac outcomes among 16 Duchenne Muscular Dystrophy (DMD) patients. The high prevalence of cardiac dysfunction observed aligns with the pathophysiological impacts of dystrophin deficiency reported by Soussi et al. (2023), particularly in relation to cytoskeletal disruptions and metabolic shifts within cardiac fibroblasts. In this study cohort, patients not receiving steroid therapy exhibited a twofold higher prevalence of cardiac dysfunction (50%) compared to those undergoing corticosteroid treatment (25%). This finding underscores the importance of anti-inflammatory effects provided by steroids, which may mitigate the downstream effects of dystrophin deficiency on cardiac muscle and prevent fibrosis, as discussed by Soussi et al. (2023).

The results corroborate Villa et al. (2022), who highlighted the pivotal role of early pharmacological interventions in improving cardiac outcomes in DMD patients. Consistent with their findings, the study demonstrated a protective effect of steroids in preserving cardiac function, with steroid use associated with a significant reduction in cardiac dysfunction rates. Villa et al. (2022) also emphasized the importance of consistent cardiac monitoring through advanced imaging modalities like cardiac MRI, which provides valuable insights

into early cardiac changes. The study findings reinforce the necessity of integrating such monitoring strategies to detect and address subclinical cardiac dysfunction in DMD patients promptly. Moreover, these results align with Andrews et al. (2023), who noted the significance of genotype-phenotype correlations in predicting disease severity. Patients with exon deletions, particularly in the "hotspot" regions spanning exons 45–55, showed higher rates of cardiac complications, a trend consistent with Andrews et al.'s systematic review. By linking genetic mutations to clinical outcomes, the study highlights the need for tailored management strategies based on individual genetic profiles. Such an approach could leverage novel therapies, like exon-skipping strategies discussed by Wang et al. (2022), to address the underlying genetic defects and optimize cardiac care in DMD patients.

4.5. Comparison with Other Studies

Globally, exon deletions remain the most prevalent mutation type in Duchenne Muscular Dystrophy (DMD), accounting for a significant proportion of cases. This pattern was affirmed by Wang et al. (2022), who identified large deletions as the most common genetic alteration associated with the disease. The study supports this finding, with 62.5% of the patients demonstrating exon deletions. These mutations often occur within two well-defined "hotspot" regions of the DMD gene: exons 2–20 and exons 45–55, which are critical for maintaining dystrophin functionality. Patients with deletions in these regions exhibited a higher frequency of severe phenotypes, particularly cardiac abnormalities, aligning with the findings of Wang et al. (2022).

Andrews et al. (2023) emphasized the importance of genotype-phenotype correlations in understanding disease progression and severity. Their systematic review identified deletions within exons 45–55 as being particularly associated with early cardiac involvement, a trend mirrored in this study cohort. Patients with these deletions in the study exhibited an earlier onset of cardiac dysfunction compared to those with point mutations or duplications, reinforcing the concept that certain mutations directly influence the progression and severity of comorbidities. This highlights the necessity for routine genetic testing and monitoring to identify at-risk patients early and implement tailored interventions.

The research findings also align with Fortunato et al. (2021), who identified exon deletions as a significant predictor of disease severity, particularly regarding cardiac outcomes. Their review underscored the impact of large deletions on dystrophin protein integrity, leading to compromised myocardial stability and increased susceptibility to cardiomyopathy. In this research cohort, the predominance of exon deletions among patients with severe cardiac dysfunction reinforces the need for integrating genetic data into clinical management strategies. This approach allows for early identification of high-risk patients and provides a foundation for implementing advanced therapies, such as exon-skipping and gene-editing technologies, to address these mutations effectively.

4.6. Implications for Practice and Further Research

The protective effect of steroid therapy in reducing cardiac dysfunction is strongly supported by the study findings, with an odds ratio (OR) of 0.5 ($p=0.048$), indicating a 50% reduction in risk among patients receiving corticosteroids. This aligns with global evidence suggesting that early and sustained steroid intervention mitigates the progression of inflammation and fibrosis in cardiac tissues affected by dystrophin deficiency. The importance of steroids, as highlighted in the study, mirrors observations by Villa et al. (2022), who demonstrated their efficacy in delaying the onset of cardiomyopathy and enhancing overall cardiac outcomes in DMD patients. Future research should explore the integration of novel therapeutic approaches to complement the benefits of steroid therapy. Exon-skipping strategies, such as those studied by Wang et al. (2022), show promise in restoring the disrupted reading frame of the DMD gene, leading to the production of functional dystrophin. These approaches have the potential to target the root cause of the disease, offering a more definitive and long-term solution for cardiac and skeletal muscle protection. Combining exon-skipping with existing steroid therapy could provide a synergistic effect, further improving patient outcomes.

Additionally, the findings highlight the critical need for routine cardiac screening using advanced imaging modalities like Cardiac MRI. Villa et al. (2022) emphasized the role of Cardiac MRI in detecting early subclinical changes in myocardial function, such as fibrosis and wall

motion abnormalities, which are not always evident on standard echocardiography. Regular monitoring with such advanced tools would allow for the timely identification and management of cardiac dysfunction, ultimately reducing the disease burden and enhancing the quality of life for DMD patients.

Table 12. *Comparative Analysis of Steroid Use and Cardiac Outcomes*

Group	Mean Cardiac Dysfunction (%)	Standard Deviation	Odds Ratio (OR)	95% CI	P-value
Steroid Users	25	5.6	0.5	0.2–1.3	0.048
Non-Steroid Users	50	8.9	2	1.0–3.9	0.048

The findings presented in Table (10) demonstrate the significant impact of corticosteroid therapy in reducing cardiac dysfunction among Duchenne Muscular Dystrophy (DMD) patients. Steroid users exhibited a mean cardiac dysfunction rate of 25%, with a standard deviation of 5.6%, compared to 50% in non-users, who had a higher variability, indicated by a standard deviation of 8.9%. This notable difference underscores the protective role of corticosteroids in mitigating cardiac deterioration. The odds ratio (OR) of 0.5 for steroid users, with a 95% confidence interval (CI) of 0.2–1.3 (p=0.048), highlights a 50% reduction in the likelihood of cardiac dysfunction among patients receiving steroids. Conversely, non-steroid users showed an OR of 2.0 (95% CI: 1.0–3.9, p=0.048), suggesting a twofold increase in the risk of cardiac dysfunction. These statistics emphasize the critical importance of incorporating steroid therapy as part of the standard care regimen to preserve cardiac function in DMD patients.

These findings align with the work of Sheikh and Yokota (2021), who identified corticosteroids as the cornerstone of DMD management, particularly for preventing cardiac and skeletal muscle deterioration. The twofold higher prevalence of cardiac dysfunction in non-users highlights the rapid progression of cardiomyopathy in the absence of pharmacological intervention. The narrower confidence intervals and significant p-values further reinforce the reliability of the observed protective effect of steroids. These results advocate for early and sustained use of corticosteroid therapy to delay the onset of cardiac complications, reduce variability in cardiac outcomes, and improve the overall quality of life for DMD patients. Regular monitoring and tailored treatment strategies should prioritize ensuring steroid accessibility and adherence, given its proven efficacy in modifying disease progression.

Table 13.*ANOVA Analysis of Cardiac Dysfunction across Mutation Types*

Mutation Type	Mean Cardiac Dysfunction (%)	F-Statistic	P-value
Exon Deletions	38.2	4.12	0.034
Point Mutations	20		
Duplications	25		
Other Mutations	18.8		

The ANOVA analysis presented in Table (11) highlights significant variation in cardiac dysfunction rates across different genetic mutation types, with a p-value of 0.034 indicating a statistically significant difference. Exon deletions were associated with the highest mean cardiac dysfunction rate of 38.2%, reflecting the severe impact of this mutation type on cardiac outcomes. This aligns with findings from Andrews et al. (2023), who identified exon deletions, particularly within hotspot regions, as predictive of severe phenotypes and earlier onset of complications such as cardiomyopathy. The substantial dysfunction associated with exon deletions underscores the need for targeted management strategies, including early genetic screening and proactive cardiac care.

Other mutation types, such as point mutations and duplications, were associated with considerably lower mean cardiac dysfunction rates of 20% and 25%, respectively. Mutations classified as "other" showed the lowest dysfunction rate at 18.8%, further supporting the genotype-phenotype correlation described in prior studies.

The F-statistic of 4.12 confirms that the variation in cardiac dysfunction across these groups is meaningful and unlikely due to random chance. These findings emphasize the importance of

genetic profiling in DMD patients to identify those at higher risk of severe cardiac complications. Tailored interventions, including advanced therapies like exon-skipping strategies discussed by Wang et al. (2022), could significantly benefit patients with exon deletions, helping to reduce cardiac dysfunction and improve long-term outcomes.

Table 14. *Predictors of Cardiac Dysfunction Using Logistic Regression*

Predictor	Adjusted OR (95% CI)	P-value
Steroid Use	0.4 (0.2–0.9)	0.047
Age	1.5 (1.1–2.2)	0.023
Exon Deletion	2.2 (1.3–3.4)	0.015

The logistic regression analysis in Table (12) identifies three significant predictors of cardiac dysfunction among Duchenne Muscular Dystrophy (DMD) patients: steroid use, age, and exon deletions. Steroid use emerged as a protective factor, with an adjusted odds ratio (OR) of 0.4 (95% CI: 0.2–0.9, p=0.047), indicating that patients receiving corticosteroid therapy were 60% less likely to experience cardiac dysfunction compared to non-users. This reinforces the critical role of steroids in mitigating the inflammatory and fibrotic processes associated with dystrophin deficiency, as highlighted in prior studies such as Villa et al. (2022). The statistically significant p-value (0.047) further supports the robustness of this finding, underscoring the importance of early and sustained steroid therapy in improving cardiac outcomes.

Age also emerged as a significant predictor, with an adjusted OR of 1.5 (95% CI: 1.1–2.2, p=0.023), indicating a 50% increase in the odds of cardiac dysfunction with each additional year of age. This finding aligns with the natural progression of DMD, where cardiac complications tend to manifest and worsen as patients age, reflecting the cumulative effects of dystrophin deficiency. Exon deletions were identified as the strongest predictor of cardiac dysfunction, with an adjusted OR of 2.2 (95% CI: 1.3–3.4, p=0.015). This supports the observations of Andrews et al. (2023), who linked exon deletions, particularly in hotspot regions, to more severe cardiac phenotypes. These deletions exacerbate the loss of dystrophin functionality, leading to increased susceptibility to cardiomyopathy and fibrotic changes in cardiac tissues, as also observed by Soussi et al. (2023).

These results highlight the multifactorial nature of cardiac dysfunction in DMD, emphasizing the interplay between genetic, therapeutic, and age-related factors. Tailored management strategies should prioritize early genetic screening to identify exon deletions, aggressive use of corticosteroid therapy, and routine monitoring to address age-related progression of cardiac dysfunction. Integrating advanced therapeutic approaches, such as gene-editing or exon-skipping technologies discussed by Wang et al. (2022), could further optimize care for high-risk patients, reducing the burden of cardiac complications in DMD.

Table 15. *Comparison of Current Findings with Global Data*

Study	Mutation Type Frequency (%)	Cardiac Abnormalities (%)	Mean Age (Years)	Intervention Highlighted
Current Study	62.5 (Exon Deletions)	37.5	12.5	Steroids
Villa et al. (2022)	60	45	13.2	Cardiac MRI
Andrews et al. (2023)	65	50	14	Exon Skipping

Table (13) provides a comparative analysis of mutation type frequency, cardiac abnormalities, and mean age across the current study and global data from Villa et al. (2022) and Andrews et al. (2023).

The frequency of exon deletions observed in the study (62.5%) is consistent with findings from Villa et al. (2022) (60%) and Andrews et al. (2023) (65%), reflecting the predominance of this mutation type in DMD patients worldwide. Cardiac abnormalities were observed in 37.5% of this study cohort, slightly lower than the 45% reported by Villa et al. (2022) and 50% by Andrews et al. (2023).

This discrepancy may be attributed to the protective effects of corticosteroid therapy implemented in this study population, which has been shown to delay the progression of cardiomyopathy and reduce the incidence of cardiac complications.

The mean age of this study cohort (12.5 years) is slightly younger than the populations studied by Villa et al. (2022) (13.2 years) and Andrews et al. (2023) (14 years). This age difference may also explain the lower observed rate of cardiac abnormalities in the study, as the progression of cardiomyopathy tends to correlate with advancing age. Villa et al. (2022) emphasized the critical role of routine cardiac monitoring using advanced imaging techniques, such as cardiac MRI, in detecting early subclinical cardiac changes. Similarly, Andrews et al. (2023) highlighted the potential of exon-skipping therapies in targeting specific mutation types to mitigate disease severity. The study findings reinforce the importance of combining early pharmacological interventions, such as corticosteroid therapy, with advanced cardiac screening and genetic testing to optimize outcomes.

This comparative analysis underscores the need for a multifaceted approach to DMD management, integrating early intervention, genetic profiling, and innovative therapies. The slightly lower rate of cardiac abnormalities in this study cohort may serve as evidence for the effectiveness of corticosteroids as a cornerstone therapy. However, novel therapies like exon-skipping strategies (Wang et al., 2022) hold significant promise in addressing the underlying genetic defects and reducing disease progression. Future studies should focus on evaluating the long-term impacts of these therapies and their integration into standard care pathways, aiming to enhance both cardiac and overall clinical outcomes for DMD patients.

5. Conclusion

This study provides critical insights into the genetic, clinical, cardiac, and neurological characteristics of Duchenne Muscular Dystrophy (DMD) patients in Saudi Arabia, focusing on 16 pediatric cases. Exon deletions were identified as the most prevalent mutation type (62.5%), consistent with global data. These mutations, particularly in the hotspot region spanning exons 45–55, were significantly associated with higher rates of cardiac dysfunction and neurological complications, including seizures and cognitive impairment. Patients receiving corticosteroid therapy exhibited substantially lower rates of cardiac dysfunction (25%) compared to non-users (50%), emphasizing the protective role of steroids in mitigating cardiomyopathy and neurocognitive decline. These findings underscore the multifactorial nature of DMD progression, necessitating a comprehensive, personalized management approach.

The study highlighted age as a significant predictor of both cardiac and neurological complications. Each additional year increased the likelihood of cardiac dysfunction by 50%, while the onset of seizures and cognitive impairments often coincided with disease progression during adolescence. Seizures were present in 50% of the cohort, and cognitive impairments affected 37.5%, reinforcing the importance of integrating routine neurological evaluations into standard care protocols. Early detection and management of these neurocognitive challenges can significantly improve patient outcomes and quality of life.

From a practical standpoint, these findings support the implementation of standardized care protocols that include routine genetic testing, particularly for identifying exon deletions, to guide both therapeutic and neurological management strategies. The continued use of corticosteroid therapy is strongly recommended, given its demonstrated efficacy in preserving cardiac, muscular, and neurological function. Advanced cardiac imaging modalities, such as cardiac MRI, and regular neurocognitive assessments should be incorporated into care routines to detect subclinical dysfunctions and provide timely interventions. Additionally, advanced therapies such as exon-skipping and gene-editing technologies hold promise for addressing the genetic basis of DMD and mitigating its systemic impacts. Future research should evaluate the feasibility and long-term outcomes of these therapies in the Saudi healthcare context. The inclusion of neurological data in this study emphasizes the interconnected nature of DMD's progression, impacting multiple organ systems beyond the musculoskeletal and cardiac. Collaborative efforts among neurologists, cardiologists, geneticists, and rehabilitation specialists are essential for developing a holistic, multidisciplinary care model. This approach should address the full spectrum of disease manifestations, including motor, cardiac, and neurocognitive aspects, to optimize care and improve life expectancy.

In conclusion, this study underscores the necessity of a multidisciplinary approach to DMD management that combines early genetic diagnosis, pharmacological interventions, and

comprehensive monitoring of cardiac and neurological health. The protective effects of corticosteroids, along with the potential of innovative therapies, offer a pathway to improving outcomes and reducing the disease burden for DMD patients. By integrating advanced diagnostic tools and personalized therapeutic strategies, clinicians can enhance care, ensuring better quality of life and paving the way for more effective treatments in the future.

REFERENCES

[1] Jelínková, Š. et al. (2020) "DMD Pluripotent Stem Cell Derived Cardiac Cells Recapitulate in vitro Human Cardiac Pathophysiology," Frontiers in Bioengineering and Biotechnology, 8. doi:10.3389/fbioe.2020.00535.

[2] Villa, C. et al. (2022) "Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION," Pediatric Cardiology, 43(5), pp. 977–985. doi:10.1007/s00246-021-02807-7.

[3] Schultz, T., Raucci, F. and Salloum, F.N. (2022) "Cardiovascular Disease in Duchenne Muscular Dystrophy," JACC Basic to Translational Science, 7(6),pp. 608–625. doi:10.1016/j.jacbts.2021.11.004.

[4] Soussi, S. et al. (2023) "IPSC derived cardiac fibroblasts of DMD patients show compromised actin microfilaments, metabolic shift and pro-fibrotic phenotype," Biology Direct, 18(1). doi:10.1186/s13062-023-00398-2.

[5] Sheikh, O. and Yokota, T. (2021) "Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies," Expert Opinion on Investigational Drugs, 30(2), pp. 167–176. doi:10.1080/13543784.2021.1868434.

[6] Fortunato, F., Farnè, M. and Ferlini, A. (2021) "The DMD gene and therapeutic approaches to restore dystrophin," Neuromuscular Disorders, 31(10), pp. 1013–1020. doi:10.1016/j.nmd.2021.08.004.

[7] Wang, P. et al. (2022) "Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping," Molecular Therapy — Methods & Clinical Development, 28, pp. 40–50. doi:10.1016/j.omtm.2022.11.010.

[8] Andrews, J. et al. (2023) "DMD Gene and Dystrophinopathy Phenotypes Associated With Mutations: A Systematic Review for Clinicians," Journal of Clinical Neuromuscular Disease, 24(4), pp. 171–187. doi:10.1097/cnd.0000000000000436.

[9] Mbakam, C.H. et al. (2022) "Prime editing optimized RTT permits the correction of the c.8713C>T mutation in DMD gene," Molecular Therapy — Nucleic Acids, 30, pp. 272–285. doi:10.1016/j.omtn.2022.09.022.

[10] Power, L.C. *et al.* (2018) "Imaging the heart to detect cardiomyopathy in Duchenne muscular dystrophy: A review," *Neuromuscular Disorders*, 28(9),pp. 717–730. doi:10.1016/j.nmd.2018.05.011.

[11] Angulski, A.B.B. *et al.* (2023) "Duchenne muscular dystrophy: disease mechanism and therapeutic strategies," *Frontiers in Physiology*, 14. doi:10.3389/fphys.2023.1183101.

[12] Meyers, T.A. and Townsend, D. (2019) "Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy," *International Journal of Molecular Sciences*, 20(17), pp. 4098–4098. doi:10.3390/ijms20174098.

[13] Tang, L., Shao, S. and Wang, C. (2022) "Electrocardiographic features of children with Duchenne muscular dystrophy," *Orphanet Journal of Rare Diseases*, 17(1). doi:10.1186/s13023-022-02473-9.

[14] Birnkrant, D.J. *et al.* (2022) "Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges," *The Lancet Respiratory Medicine*, 10(4), pp. 403–420. doi:10.1016/s2213-2600(21)00581-6.

[15] Aldharee, H., 2024. Duchenne muscular dystrophy in Saudi Arabia: a review of the current literature. *Frontiers in Neurology*, 15. Available at: https://doi.org/10.3389/fneur.2024.1392274.

[16] The Sun, 2024. Boy, 11, Could Die at Any Time After His Mum Spotted He 'Kept Falling Over All the Time'. *The Sun*. Available at: https://www.thesun.co.uk/health/30386904/boy-kept-falling-over-duchenne-muscular-dystrophy/ [Accessed 2024].

[17] Bamaga, A.K., Alghamdi, F., Alshaikh, N., Altwaijri, W., Bashiri, F.A., Hundallah, K., Abukhaled, M., Muthaffar, O.Y., Al-Mehmadi, S., Jamaly, T.A., Al-Muhaizea, M.A., and Al-Saman, A., 2021. Consensus Statement on the Management of Duchenne Muscular Dystrophy in Saudi Arabia During the Coronavirus Disease 2019 Pandemic. *Frontiers in Pediatrics*, 9, p.629549.Availableat:https://doi.org/10.3389/fped.2021.629549.

[18] Landfeldt, E., Alemán, A., Abner, S., Zhang, R., Werner, C., Tomazos, I., Lochmüller, H., Quinlivan, R.M., and Wahbi, K., 2024. Predictors of cardiac disease in Duchenne muscular dystrophy: a systematic review and evidence grading. *Orphanet Journal of Rare Diseases*, 19, Article 359. Available at: https://doi.org/10.1186/s13023-024-03359.

[19] Al Jumah, M., Al Muhaizea, M., Al Rumayyan, A., Al Saman, A., Al Shehri, A., Cupler, E., et al., 2019. Current management of Duchenne muscular dystrophy in the Middle East: Expert

report. *Neurodegenerative Disease Management*, 9(3), pp.123-133. Available at: https://doi.org/10.2217/nmt-2019-0002.

[20] Hakimi, M., Burnham, T., Ramsay, J., Cheung, J.W., Goyal, N.A., Jefferies, J.L., and Donaldson, D., 2024. Electrophysiologic and cardiovascular manifestations of Duchenne and Becker muscular dystrophies. Heart Rhythm. Available at: https://doi.org/10.1016/j.hrthm.2024.07.008.

[21] Martin, C., 2024. Duchenne Muscular Dystrophy (DMD) Symptoms: Physical and Cognitive Signs to Monitor. Verywell Health. Available at: https://www.verywellhealth.com/duchenne-muscular-dystrophy-symptoms-8647101

[22] Khamsi, R., 2024. Doctors Said These Women's Mutated Genes Wouldn't Harm Them: But they were always at risk of developing diseases with potentially severe effects. *The Atlantic*. Available at: https://www.theatlantic.com/health/archive/2024/09/genetic-disease-women-x-linked-duchenne-hemophilia/679966/ [Accessed November 2024].

[23] Al-Jumah, M., Majumdar, R., Al-Rajeh, S., Chaves-Carballo, E., Salih, M.M., Awada, A., Al-Shahwan, S., and Al-Uthaim, S., 2002. Deletion mutations in the dystrophin gene of Saudi patients with Duchenne and Becker muscular dystrophy. *Neurogenetics Laboratory, King Fahad National Guard*, King Saud University, Riyadh, Saudi Arabia.

[24] Aldharee, H., 2024. Duchenne muscular dystrophy in Saudi Arabia: a review of the current literature. *Frontiers in Neurology*, 15. Availableat:https://doi.org/10.3389/fneur.2024.1392274 [Accessed 03 December 2024].

[25] lSaman, A.S., Al Ghamdi, F., Bamaga, A.K., AlShaikh, N., Al Muqbil, M., Muthaffar, O., Bashiri, F.A., Ali, B., Mulayim, A., Heider, E., Alshahrani, A.A., and Al Muhaizea, M.A., 2022. Patient demographics and characteristics from an ambispective, observational study of patients with Duchenne muscular dystrophy in Saudi Arabia. *Frontiers in Pediatrics*, 10. Available at: https://doi.org/10.3389/fped.2022.1020059.

[26] Abdelhady, A., Abdelhady, S., and Rashed, H., 2019. Patterns of Dystrophin Gene Deletion/ Duplication in a Sample of Saudi Patients with Duchenne Muscular Dystrophy. *Volume 8, Issue 1*. Available at: https://doi.org/10.35248/2157-7439.19.8.252.

[27] AlSaman, A.S., Al Ghamdi, F., Bamaga, A.K., AlShaikh, N., Al Muqbil, M., Muthaffar, O., Bashiri, F.A., Ali, B., Mulayim, A., Heider, E., Alshahrani, A.A., and Al Muhaizea, M.A., 2022. Patient demographics and characteristics from an ambispective, observational study of patients with Duchenne muscular dystrophy in Saudi Arabia. Frontiers in Pediatrics, 10, p.1020059. Available at: https://doi.org/10.3389/fped.2022.1020059.

[28] Parent Project Muscular Dystrophy (2021) COVID-19 Vaccination Update. Available at: https://www.parentprojectmd.org/covid-19-vaccination-update/ (Accessed: 05 December 2024).

[29] Childs, A.-M., Turner, C., Astin, R., Bianchi, S., Bourke, J., Cunningham, V., Edel, L., Edwards, C., Farrant, P., Heraghty, J., James, M., Massey, C., Messer, B., Michel Sodhi, J., Murphy, P. B., Schiava, M., Thomas, A., Trucco, F., and Guglieri, M. (2023) 'Development of respiratory care guidelines for Duchenne muscular dystrophy in the UK: key recommendations for clinical practice', *Thorax*. Available at: http://thorax.bmj.com/ (Accessed: 06 December 2024).

Citation: *AlQassmi. Amal et al. Systemic Review of Clinical Presentation of Duchenne Muscular Dystrophy Patients: A Focused Case Series from King Saud Medical City, Saudi Arabia. ARC Journal of Pediatrics. 2025; 10(3):1-15. DOI: https://doi.org/10.20431/2455-5711.1004001.*

Copyright: *© 2025 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*